Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy:
This is a Phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating
RPT904, a next-generation anti-IgE monoclonal antibody, in people with food allergy.
RPT9...
Age: 12 - 55 years
Gender: All
Efficacy of Tezepelumab in Peanut Oral Immunotherapy
The proposed study is a proof-of-concept Phase 2, double-blind, randomized placebo-controlled clinical trial evaluating the safety and efficacy of tezepelumab and peanut Oral Immunotherapy (OIT) for the treatment of peanut allergy. Study participation is divided into 3 ...
Age: 12 - 55 years
Gender: All
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
The primary objective of this study is to assess the 6-month safety of DBV712 250
micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.
Age: 1 year - 3 years
Gender: All
Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
Open-label, follow-up study for subjects who completed the EPITOPE study.
Age: 2 - 5 years
Gender: All
PALISADE Follow-on Study (ARC004)
The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through characterized oral desensitization immunotherapy (CODIT) in peanut-allergic children and adults who have completed the ARC003 study.
Age: 4 - 55 years
Gender: All
HAL-MPE1 Safety and Tolerability Study
The aim of this study is to confirm safety and tolerability of incremental doses of HAL-MPE1 subcutaneous immunotherapy (SCIT) in peanut allergic adults, and subsequently assess the safety and tolerability in adolescents and children with peanut allergy.
Age: 5 - 50 years
Gender: All